BitterLiebe, based in Mannheim (Germany), is a direct-to-consumer premium health brand for gastrointestinal supplements in the DACH region. Vendis Capital’s participation in BitterLiebe represents the eighth investment within Vendis Capital III, the €300 million fund that was launched in 2019, and its sixth acquisition in Germany.

The Reed Smith team advising on the deal was led by Frankfurt office managing partner Dr. Octávio de Sousa (Corporate) involving the recently appointed leverage finance partner Dr. Oliver Hahnelt; with further support from partners Wim Vandenberghe (Regulatory/Commercial), Dr. Martin Bünning (Tax), Dr. Andreas Jürgens (Corporate), Harald Heller (Real Estate), Christian Filippitsch (Antitrust) and Christian Leuthner (Data Protection); counsels Dr. Nikolas Koutsós (Finance), Markus Cejka (Finance) and Dr. Christoph Mikyska (IP) and associates Cecilia Manny (Corporate), Max von Döhren (Corporate), Vincent Magotsch (Employment), Jonas Weimert (IP), Jonathan Diehl (Real Estate) and Moritz Reinhard (Real Estate).

de Sousa commented: “We are delighted to have advised Vendis Capital on its strategic investment in BitterLiebe, which will support the next stage of the company’s growth. For Reed Smith this transaction is another testament of our capability to provide seamless advice on private equity and leverage finance transactions.”